News

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in a fireside chat at the BofA

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance.

Financial Summary

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), evaluating outcomes with the

Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 3:40 PM (PDT) at the

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2025 third quarter ended March 31, 2025.

Fiscal-year

ICON plc (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today reported its financial results for the first quarter ended March 31, 2025.

CEO

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the initial cohort of its Charles River Incubator Program (CIP). Launched in December 2024, the program offers early-stage

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common

Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive

Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer at the 2025

Novocure (NASDAQ: NVCR) gab heute bekannt, dass Optune Lua^® die CE-Kennzeichnung (Conformité Européenne) für die Behandlung von erwachsenen Patienten mit metastasierendem nicht-kleinzelligem

Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that one of its AI-powered applications, Stanson Health CodingCare, is Under Construction in Toolbox on Epic

Charles River Laboratories International, Inc. (NYSE: CRL), ahead of the American Association for Cancer Research® (AACR) Annual Meeting in Chicago, IL, has announced updates to its comprehensive

Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)

Acadia Healthcare (NASDAQ: ACHC) (“Acadia” or the “Company”) today announced that it will release its first quarter 2025 financial results on Monday, May 12, 2025, after the close of the market

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2025 financial results on Wednesday, May 7^th, before the market opens. A conference call has been scheduled to